Glimepiride/metformin (2/500 mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin (2/500 mg) fixed-dose combination (FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities to allow the marketing of the test formulation. We evaluated the comparative bioavailability and tolerability of the test and reference formulations in healthy male adult volunteers.This single-dose, randomized, double-blind, two-way crossover trial was conducted at Bestian Medical Center in Bucheon, Korea. In total, 40 male Korean volunteers were enrolled. The subjects were randomized to receive an FDC tablet containing the glimepiride/metformin (2/500 mg) test or reference formulation, and pharmacokinetic(PK) parameters were measured. After a 1-week washout period, the other formulation was administered and the PK parameters were measured again. The C max and AUC t were determined from blood samples obtained at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 h after drug administration. Bioequivalence was considered established if the 90% CIs of the geometric mean ratios(GMRs) of the testto-reference formulations for C max and AUC t were within the predetermined regulatory range of 80-125%. Intotal, 40 healthy male subjects were enrolled and completed the study (mean [SD] [range, 164-189 cm]). The GMRs(90% CI) of the glimepiride C max and AUC t were 1.006(0.947-1.069) and 1.010(0.953-1.071), respectively. For metformin, the values were 1.019(0.959-1.083) and 1.035(0.989-1.084), respectively. The test and reference formulations had similar PK parameters. The test formulation of glimepiride/metformin (2/500 mg) FDC tablets met the Korean regulatory criteria for bioequivalence.
Introduction
Type 2 diabetes mellitus (DM) is a complex disease characterized by a range of metabolic defects, imbalances, and abnormalities affecting multiple organ systems. Three key defects herald the onset of hyperglycemia and type 2 diabetes: (1) impaired insulin action/insulin resistance in muscle, liver, and adipose tissue;(2) elevated prandial and postprandial hepatic glucose production, resulting, in part, from defects in glucagon regulation; and (3) diminished insulin secretion, resulting from defects in β cell function adequate glycemic control with a sulfonylurea agent alone (18). The glucose-lowering effect of metformin is primarily the result of reduced hepatic glucose output, through the inhibition of gluconeogenesis and glycogenolysis (19) .
The sulfonylurea glimepiride might offer some advantages as a component of a fixed-dose combination(FDC) tablet with metformin due to its more prominent extrapancreatic activity and more favorable safety profile, compared with other sulfonylureas (20) (21) (22) (23) .The combination of glimepiride and metformin was approved by the US Food and Drug Administration in 1999.
The present bioequivalence study was designed to provide data to submit to regulatory authorities to allow marketing of the test formulation, which is the first generic glimepiride/metformin (2/500 mg) FDC tablet formulation approved in Korea. In this study, we compared the pharmacokinetic (PK) properties, safety profiles, and relative bioavailability of the generic (test) and brand(reference) glimepiride/ metformin FDC tablets in healthy male Korean volunteers.
Experimental

Subjects
In total, 40 healthy Korean male volunteers participated. The subjects ranged in age from 19-30 years (mean ± SD, 23.2 ± 2.26 years) and mass (1-6).Various medications have been approved for the treatment of type 2 DM in many countries. Combination treatments decrease the risk of medication non-compliance and have cost-saving effects (7, 8) .The most common combination regimens are (I) a sulfonylurea with metformin or a thiazolidinedione (TZD) and (II) metformin with a TZD (9). Metformin with a sulfonylurea causes greater reductions in HbA1c than either drug alone (10-12).
Glimepiride is an oral sulfonylurea antihyperglycemic agent. The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic β cells. Extrapancreatic effects may also play a role (13-15).Glimepiride is indicated for the treatment of type 2 DM at are recommended dosage of 1-8 mg/day for adults and is typically administered with other antihyperglycemic agents such as metformin or TZDs to provide adequate glycemic control (9,16).
Metformin, a biguanide glucose-lowering agent, is commonly used to manage type 2 DM(16). Monotherapy with metformin is used as an adjunct to diet to manage type 2 DM in patients whose hyperglycemia cannot be controlled by diet alone (17).Metformin may also be used in combination with other antidiabetic agents in patients with type 2 DM who do not achieve No subject had any significant cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, or hematological disorder, as determined by medical history and physical examinations; the latter included assessments of the subjects' vital signs and clinical laboratory values(hematology, blood chemistry, and urinalysis). Furthermore, each subject was physically normal and had no previous history of significant illness or hypersensitivity to any drug. Finally, the subjects were asked to refrain from taking alcohol, caffeine, and any other drugs for at least 1week before and throughout the study period.
The study protocol was approved by the Institutional Review Board of BMC. All procedures were performed according to Good Clinical Practice guidelines and the Declaration of Helsinki for biomedical research (24) involving human subjects. All participants provided written informed consent to join the study before the screening test for eligibility.
Study design and materials
This bioequivalence study was conducted as a randomized, single-dose, two-period, two-sequence, crossover study. There were two treatment periods separated by a 1-week washout period, which was more than five times the half-life, as determined in previous studies (25, 26) . A table of random numbers was used to assign subjects in a 1:1 ratio to receive the test drug or reference drug. All subjects fasted for at least 10h before administration. The study drug was given with 240 mL of water, and all subjects abstained from food until 4 h after dosing. After a washout period of 7 days, the same procedure was repeated with the other formulation. Dietary, smoking, and drug-herbal product restrictions were maintained throughout the study period.
Blood sampling
Blood samples for PK analyses were collected before and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 , and 24 h after drug administration. They were drawn through an indwelling intravenous catheter placed in the forearm vein and transferred to a heparinized tube. After the first 1 mL of blood was discarded, a 9 mL sample was collected. Next, the cannula was flushed with 1 mL of normal saline to prevent clotting. Following centrifugation (3,000x g, 10min, 4 °C), plasma samples were transferred to microcentrifuge tubes and immediately stored at -70 °C until analysis. After a washout period of 7 days, the study was repeated in the same manner to complete the crossover design.
Measurement of plasma glimepiride and metformin
All plasma samples were handled and analyzed by BIOSUNTEK Laboratory Co., Ltd. For the quantification of glimepiride, the method had a linear quantifiable range of 2-400 ng/mL and a γ 2 of 0.997. The lower limit of quantitation(LLOQ) was 2 ng/mL. The intraday precision ranged from 3.31-8.27%, while the inter day precision ranged from 0.41-5.55%. The intraday accuracy was 102.6-103.6% while the inter day accuracy was 102.0-103.6%. The analyte was stable in human plasma following three freeze-thaw cycles, in plasma after storage for 6 h at room temperature, in stock solution after storage for 6 h at room temperature, and in the HPLC auto sampler after storage for 24 h.
For the quantification of metformin, the method had a linear quantifiable range of 5-2000 ng/mL and a γ 2 of 0.998. The LLOQ was 5 ng/ mL. The intraday precision ranged from 0.96-2.18%, while the inter day precision ranged from 3.26-9.77%. The intraday accuracy was 88.9-96.7% while the inter day accuracy was 98.2-100.2%. The analyte was stable in human plasma following three freeze-thaw cycles, in plasma after storage for 6 h at room temperature, in stock solution after storage for 6 h at room temperature, and in the HPLC auto sampler after storage for 24 h.
PK analysis
Changes in the plasma concentrations of glimepiride and metformin in each subject were analyzed using non-compartmental mental PK models and individual PK parameters were assessed using the BA-CALC program(KFDA, 2008, 1.0.0, Korea).PK parameters included the area under the plasma concentration-versustime curve from 0 h to the last measurable concentration (AUC t ), which was calculated using the linear trapezoidal rule, maximum plasma concentration (C max ),and time required to reach the maximum plasma concentration (T max ).The terminal elimination rate constant(λ Z ) was estimated using linear regression of the log-linear decline of individual plasma concentration-time data. The individual t ½ was calculated for each subject as ln2/λ Z . AUC ∞ was calculated as AUC t + C last /λ Z , where C last was the last measurable concentration (30).
Statistical analyses
The demographic characteristics of the enrolled subjects were summarized using descriptive statistics. We used a sample size of 40, as required by the Korean Food and Drug Administration, because of the potential for dropouts during the study. Statistical analysis was performed using the K-BE test program(KFDA, 2007, 1.1.0, Korea).The GMRs of the test and reference values for AUC t and C max were calculated. The formulations were assumed bioequivalent if the 90% CIs for the GMRs of the test formulation to the reference formulation were from 0.8 to 1.25.
Results and Discussion
In total, 40 adult Korean male volunteers participated in this bioequivalence study. Physical examinations conducted before starting the study indicated that the subjects were healthy. There were no dropouts during the study period. No clinical AEs were reported. Figure 2 shows the mean ± SD plasma concentration-time profiles of glimepiride and metformin after administration of two formulations of a glimepiride/metformin (2/500 mg) FDC tablet, and Table 2 shows the values of the PK parameters for the test and reference formulations. The formulations had very similar AUC t and C max values. Table 3 shows the GMRs of the reference and test drugs. The GMRs (90% CIs) of C max and AUC t for glimepiride and T max , h † 2.2(0.8,4) 2.0(0.9,5.0) T max , h † 2.2(0.5, 4) 2.5(0.8, 4) Table 2 . Pharmacokinetic parameters following administration of the test and reference formulations of glimepiride/metformin 2/500 mg FDC tablet, in fasting, healthy male subjects(n=40) † Median(minimum, maximum). metformin ranged from 0.8 to 1.25. This meets the Korean regulatory criteria for bioequivalence.
The results of the current study indicate that a generic formulation of glimepiride/metformin (2/500 mg)FDC tablet met the regulatory requirements for assuming bioequivalence to the reference formulation, as established by the Korean Food and Drug Administration.
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